Financial Analysis: Mymd Pharmaceuticals (NASDAQ:QCLS) & Hewlett Packard Enterprise (NYSE:HPE)

Hewlett Packard Enterprise (NYSE:HPE) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Volatility & Risk

Hewlett Packard Enterprise has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, Mymd Pharmaceuticals has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Hewlett Packard Enterprise and Mymd Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hewlett Packard Enterprise	0	7	10	0	2.59
Mymd Pharmaceuticals	1	0	0	0	1.00

Hewlett Packard Enterprise presently has a consensus price target of $69.93, indicating a potential upside of 31.78%. Given Hewlett Packard Enterprise’s stronger consensus rating and higher possible upside, analysts clearly believe Hewlett Packard Enterprise is more favorable than Mymd Pharmaceuticals.

Profitability

This table compares Hewlett Packard Enterprise and Mymd Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hewlett Packard Enterprise	3.94%	11.91%	3.84%
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

Valuation and Earnings

This table compares Hewlett Packard Enterprise and Mymd Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hewlett Packard Enterprise	$34.30 billion	2.05	$57.00 million	$1.07	49.60
Mymd Pharmaceuticals	N/A	N/A	-$11.63 million	($20.69)	-0.14

Hewlett Packard Enterprise has higher revenue and earnings than Mymd Pharmaceuticals. Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than Hewlett Packard Enterprise, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

80.8% of Hewlett Packard Enterprise shares are held by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 0.4% of Hewlett Packard Enterprise shares are held by insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Hewlett Packard Enterprise beats Mymd Pharmaceuticals on 11 of the 13 factors compared between the two stocks.

About Hewlett Packard Enterprise

Hewlett Packard Enterprise Company provides solutions that allow customers to capture, analyze, and act upon data seamlessly in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and Japan. It operates in six segments: Compute, HPC & AI, Storage, Intelligent Edge, Financial Services, and Corporate Investments and Other. The company offers general purpose servers for multi-workload computing and workload-optimized servers; HPE ProLiant rack and tower servers; HPE Synergy; HPE Alletra, HPE GreenLake, Zerto, HPE InfoSight, and HPE CloudPhysics storage products; HPE Cray EX, HPE Cray XD, and converged edge systems; and HPE Superdome Flex, HPE Nonstop, and HPE Integrity products. It also provides HPE Aruba products that includes hardware products, such as Wi-Fi access points, switches, and gateways; HPE Aruba Networking software and services comprising cloud-based management, network management and access control, analytics and assurance, software-defined wide-area networking, network security, analytics and assurance, and location services software; and professional and support services, as well as as-a-service and consumption models. In addition, the company offers leasing, financing, IT consumption, and utility programs and asset management services for customers to facilitate technology deployment models and the acquisition of various IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others; consultative-led services; HPE Ezmeral Container Platform; HPE Ezmeral Software Container Platform and HPE Ezmeral Software Data Fabric; OpsRamp; and Hewlett Packard Labs. It serves commercial and large enterprise groups, such as business and public sector enterprises; and through various partners comprising resellers, distribution partners, original equipment manufacturers, independent software vendors, systems integrators, and advisory firms. The company was founded in 1939 and is headquartered in Spring, Texas.

About Mymd Pharmaceuticals

TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.